Related Experiment Video
Updated: May 31, 2025

Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
Machine Learning-driven Identification of the Honeymoon Phase in Pediatric Type 1 Diabetes and Optimizing Insulin
1Narasaraopeta Engineering College, Department of Computer Science and Engineering, Andhra Pradesh, India
Objective:
The honeymoon phase in type 1 diabetes (T1D) represents a temporary improvement in glycemic control but may complicate insulin management. The aim was to develop and validate a machine learning (ML)-driven method for accurately detecting this phase to optimize insulin therapy and prevent adverse outcomes.
Methods:
Data from pediatric T1D patients aged 6-17 years, including continuous glucose monitoring data, glucose management indicator (GMI) reports, hemoglobin A1c (HbA1c) values, and patient medical history, were used to train ML models including long short-term memory (LSTM) networks, transformer models, random forest, and gradient boosting machines (GBMs). These were designed to analyze glucose trends and identify the honeymoon phase in T1D patients.
Results:
The transformer model achieved the highest accuracy at 91%, followed by GBMs at 89%, LSTM at 88%, and random forest at 87%. Key features, such as glucose variability, insulin adjustments, GMI values, and HbA1c levels were critical to model performance. Accurate identification of the honeymoon phase enabled optimized insulin adjustments, enhancing glucose control and reducing hypoglycemia risk.
Conclusion:
The ML-driven approach provides a robust method for detecting the honeymoon phase in T1D patients, demonstrating potential for improved personalized insulin management. The findings suggest significant benefits in patient outcomes, with future research focused on further validation and clinical integration.
More Related Videos
Related Concept Videos
Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Insulin: Dosing Regimen and Adverse Effects
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Diabetes Mellitus: Type 2 and Gestational
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Diabetes: Symptoms, Diagnosis, and Complications
Insulin Formulations: Types and Delivery
Short-acting insulins are divided into...

